Several reports suggest that posttransfusion hepatitis C causes more aggressive histological activity than disease that is acquired via other routes. We sought to determine whether mode of transmission affects disease outcome. We studied the demographics, presenting laboratory data, and clinical cou
Mode of transmission of hepatitis C and clinical outcome correction
β Scribed by Damian Dowling
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 24 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Most patients with an acute infection of hepatitis C virus (HCV) will develop chronic hepatitis, and only about 15β20% of the cases will resolve spontaneously. The mechanism for the different outcomes in patients with acute HCV infection remains unclear. HCV genotype has been recognized
Medical opinion varies considerably regarding the transmission of hepatitis C virus (HCV) through sexual contact. Based on the study design, representativeness of the study population, and the methods used for case ascertainment, we analyzed 80 qualifying reports regarding the evidence for or agains
Such nonpercutaneous routes of hepatitis C virus (HCV) transmission of hepatitis C. Whereas direct, percutaneous inoculation, eg, via transfusion or self-injection of addictive transmission as sexual and perinatal spread are relatively inefficient. Several observations have been cited to support a r
Hepatitis B (HBV) and C viral (HCV) dual-infectionassociated liver disease is an uncommon indication for liver transplantation. The clinical and virologic outcomes in such patients have not been well studied. We retrospectively studied 13 patients with hepatitis B surface antigen (HBsAg) and antibod
## Abstract Clinical relevance of occult hepatitis C virus (HCV) and/or hepatitis B virus (HBV) infection(s) remains uncertain years after interferon (IFN) therapy for chronic hepatitis C. By 1993, 38 sustained virological responders (SVRs) showing HCV RNA clearance at 6 months postβtreatment and 3